PubMed Journals Articles About "Biotech News Recap NASH Readout Coming CymaBay Therapeutics" RSS

18:13 EDT 15th June 2019 | BioPortfolio

Biotech News Recap NASH Readout Coming CymaBay Therapeutics PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Biotech News Recap NASH Readout Coming CymaBay Therapeutics articles that have been published worldwide.

More Information about "Biotech News Recap NASH Readout Coming CymaBay Therapeutics" on BioPortfolio

We have published hundreds of Biotech News Recap NASH Readout Coming CymaBay Therapeutics news stories on BioPortfolio along with dozens of Biotech News Recap NASH Readout Coming CymaBay Therapeutics Clinical Trials and PubMed Articles about Biotech News Recap NASH Readout Coming CymaBay Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biotech News Recap NASH Readout Coming CymaBay Therapeutics Companies in our database. You can also find out about relevant Biotech News Recap NASH Readout Coming CymaBay Therapeutics Drugs and Medications on this site too.

Showing "Biotech News Recap NASH Readout Coming CymaBay Therapeutics" PubMed Articles 1–25 of 2,100+


Who falls for fake news? The roles of bullshit receptivity, overclaiming, familiarity, and analytic thinking.

Fake news represents a particularly egregious and direct avenue by which inaccurate beliefs have been propagated via social media. We investigate the psychological profile of individuals who fall prey to fake news.

Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.

Nonalcoholic steatohepatitis (NASH) afflicts 20-36% of individuals with nonalcoholic fatty liver disease (NAFLD). A lipotoxic hepatic environment, altered innate immune signaling and inflammation are defining features of progression to NASH. Activated resident liver macrophages express folate receptor beta (FR-β) which may be an indicator of progression from steatosis to NASH. The goals of this study were to characterize FR-β protein expression in human NAFLD and rodent models of NASH, and demonstrate liv...

Lipid mediators of liver injury in nonalcoholic fatty liver disease.

Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of histopathological phenotypes ranging from simple steatosis to more severe liver disease associated with cell injury including nonalcoholic steatohepatitis (NASH), advanced fibrosis and cirrhosis. Only a subset of patients with NAFLD develop NASH from yet incompletely understood mechanisms. Emerging data suggest lipid species other than triglycerides as contributors to the pathogenesis of NASH. In this mini review, we focus on the recent data ...

The role of 3D-MRE in the diagnosis of NASH in obese patients undergoing bariatric surgery.

The lack of reliable, noninvasive methods to diagnose early nonalcoholic steatohepatitis (NASH) is a major unmet need. We aimed to determine the diagnostic accuracy of 3D-MRE, with shear stiffness measured at 60 Hz, damping ratio at 40 Hz, and MRI proton density fat fraction (MRI-PDFF) in the detection of NASH in individuals undergoing bariatric surgery. Obese adults at risk for NASH were enrolled between 2015-2017 (prospective cohort, n=88) and 2010-2013 (retrospective cohort, n=87). The imaging protocol c...

Patient-reported outcomes for NAFLD/NASH: rational for expanded use.

It is estimated that one in four adults around the world has non-alcoholic fatty liver disease (NAFLD), a condition that can lead to non-alcoholic steatohepatitis (NASH), serious liver damage and, ultimately, death. The arrival of new treatment options and prevention strategies for NAFLD/NASH will result in an increasing number of clinical trials targeting this disease. Younossi outlined (1) the increasing importance of including patient-reported outcomes (PROs) in future clinical trials for NAFLD/NASH trea...

Is the Early Detection of Pancreatic Cancer Possible? It Is Good News, Bad News.

Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.

Nonalcoholic fatty liver disease (NAFLD) includes nonalcoholic fatty liver (NAFL), nonalcoholic steato hepatitis (NASH) and NASH cirrhosis. NAFLD is the leading cause of liver diseases in the Western world (Central Europe, United States). The NAFLD incidence increases because of increasing type 2 diabetes and obesity. This article reviews the scientific findings of epidemiology, diagnostic, and therapeutic management of NAFLD. Lifestyle modifications (low-caloric Mediterranean diet and exercise training) to...

IL-17A-mediated ERK1/2/p65 Signaling Pathway is Associated with Cell Apoptosis after Non-alcoholic Steatohepatitis.

Interleukin (IL)-17A is pro-inflammatory cytokine which has been identified as a noninvasive marker of the pathogenesis of non-alcoholic steatohepatitis (NASH). However, the underlying role of IL-17A in NASH progression remains unclear. This study was designed to investigate the biological function and molecular mechanism of IL-17A in the induction of NASH. The results showed that IL-17A was highly expressed in high-fat diet (HFD)-induced NASH mouse model. Intravenous injection of IL-17A exacerbated steatoh...

New aspects of nonalcoholic steatohepatitis.

During the past 10 years nonalcoholic fatty liver disease (NAFLD) has moved more and more into the focus of attention of clinical research. The term NAFLD comprises the simple nonalcoholic steatosis or fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). As the incidence of NAFLD has dramatically increased, it is expected that during the coming years NASH in particular will become the main reason for liver transplantation in industrialized countries. In addition, it has become evident that scirrhotic...

Youth and young adult exposure to and perceptions of news media coverage about e-cigarettes in the United States, Canada and England.

News media coverage has the potential to shape awareness and perceptions of e-cigarettes, but little is known about youth and young adult exposure to e-cigarette news. We analyzed news exposure measures on Wave 1 of the ITC Youth Tobacco and E-cigarette Survey, conducted in Canada, England, and the U.S. Web-based surveys were completed by 16-19-year-olds in July/August 2017 (n = 12,064). The prevalence of exposure to e-cigarette news and its perceived valence is provided. Logistic regression was used to...

Good News and Bad News.

Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.

Hepatic fibrosis increases mortality in humans with non-alcoholic steatohepatitis (NASH), but it remains unclear how fibrosis stage and progression affect the pathogenic mechanisms of NASH. This study investigates the transcriptional regulation and the impact of fibrosis stage, of pathways relating to hepatic lipid and cholesterol homeostasis, inflammation and fibrosis using RT-qPCR in the guinea pig NASH model. Animals were fed a chow (4% fat), a high-fat (20% fat, 0.35% cholesterol) or high-fat/high-sucro...

Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.

In addition to potentially progressing to either cirrhosis or hepatocellular carcinoma, non-alcoholic steatohepatitis (NASH) is currently the leading indication for liver transplantation. Nintedanib has been clinically used to treat idiopathic pulmonary fibrosis for many years, but its effects in an animal model of NASH have not been tested. The purpose of this study was to evaluate the effects of nintendanib on NASH in choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD)-fed mice.

Incorporating Weight Loss Medications into Hepatology Practice for Nonalcoholic Steatohepatitis.

There is an urgent need for practical approaches to patients with non-alcoholic steatohepatitis (NASH). Total body weight loss (TBWL) is an important approach because its effects are amplified in the liver, with 10% TBWL resulting in a 50% loss of liver triglycerides, and improvement in all aspects of NASH histology. Lifestyle changes are the first step in addressing TBWL, but uncommonly result in the range (7-10%) required to improve liver histology in NASH. Weight loss medications (WLM) are an effective a...

Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, particularly in obese and type 2 diabetic individuals. NAFLD ranges in severity from benign steatosis to nonalcoholic steatohepatitis (NASH); and NASH can progress to cirrhosis, primary hepatocellular carcinoma (HCC) and liver failure. As such, NAFLD has emerged as a major public health concern. Herein, we used a lipidomic and transcriptomic approach to identify lipid markers associated with western diet (WD) induce...

NASH and HCC Are Driven by Different Signaling Pathways with a Common Regulator.

Oxidative stress is uniformly present in non-alcoholic steatohepatitis (NASH), but its role in the development of liver inflammation and hepatocellular cancer (HCC) and the relationship between these two pathologies are poorly understood. In a recent issue of Cell, Grohmann et al. (2018) demonstrate a vital role of obesity-induced oxidative stress in deactivating the phosphatase TCPTP, resulting in activation of STAT-1 and STAT-3, which each independently drive the development of NASH and HCC, respectivel...

News from TCT San Diego 2018: Intracoronary Imaging: New evidence on optimization of stent implantation and detection of patients and vessels at risk presented at Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San Diego.

Annual Meeting Recap.

Bouchardatine analogue alleviates NAFLD/NASH in high fat fed mice via blunting ATP synthase activity.

Non-alcoholic hepatic fatty liver disease (NAFLD) is a manifestation of metabolic syndrome (MetS) in liver where non-alcoholic steatohepatitis (NASH) is its advanced stage. R17 is synthesized from bouchardatine with benefits for MetS but untested therapeutic effects in liver. The present study examined the pharmacological effects of R17 for NAFLD/NASH and its molecular mode of action.

How to say bad news without compromising the patient's humanity.

Communicating bad news is still a communication challenge in the field of care and, despite the there being methodologies that allow us to humanize information that has a great impact on people's lives, it is usually neither taught nor used in daily life, thus bringing about emotional outcomes, that can be, at times, more serious than the disease itself. The art of communication is a component of medical praxis, so training in the early years of medicine on methodologies related to the communication of bad ...

Antifibrotic Effects of 1,25(OH)D on Nonalcoholic Steatohepatitis in Female Mice.

Postmenopausal women have a higher risk of nonalcoholic steatohepatitis (NASH) along with an increase in age, and vitamin D deficiency occurs in some patients with NASH.

A Tale of Two Complications of Obesity: Nonalcoholic steatohepatitis (NASH) and Hepatocellular carcinoma (HCC).

Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in developed countries and its incidence is rapidly increasing. Cirrhosis, and the dreaded complication of hepatocellular carcinoma (HCC), are the major drivers of morbidity and mortality in NASH. Conventional understanding has been that chronic liver damage leads to a cycle of cell death, regeneration and fibrosis during which HCC precursor cells undergo malignant transformation and lead to cancer initiation. This article...

Repositioning of niclosamide ethanolamine (NEN), an anthelmintic drug, for the treatment of lipotoxicity.

Nonalcoholic steatohepatitis (NASH) is a common liver disease associated with metabolic disorders, including obesity and type 2 diabetes (T2D). Despite its worldwide prevalence, there are no effective drugs for the treatment of NASH. The progression of NASH is mainly accelerated by reactive oxygen species (ROS)-induced lipotoxicity. The transcription factor known as nuclear factor erythroid 2-related factor 2 (Nrf2) is pivotal for the elimination of ROS. Accordingly, activators of Nrf2 have been implicated ...

A good idea badly implemented? Revised National Early Warning Score 2 in community settings.

The revised National Early Warning Score (NEWS2), a tool used to measure acute deterioration in hospital, has been introduced in acute NHS hospitals and ambulance services. Community nurses report that when they call 999 requesting an ambulance to take a person to hospital, they are asked to provide a NEWS score. They report that when the NEWS score is high, ambulance staff prioritise the call. The NEWS score is being introduced in the community by default. This article will outline how the NEWS score is ca...

Quick Search